Future studies should focus on the following areas: First, clarifying the specific role of eIF4E-dependent translation and its regulatory mechanisms in different types of pain (e.g., inflammatory pain, neuropathic pain, etc.); second, investigating how to precisely target eIF4E without triggering other adverse effects; and third, evaluating the safety and efficacy of existing and potential new drugs for chronic pain patients, while also understanding the interactions between eIF4E and other signaling pathways and how they collectively modulate pain transmission. This evidence concerns the gene EIF4E and chronic cystitis.